摘要
多项研究表明,人表皮生长因子受体2(HER2)扩增可能是RAS野生型转移性结直肠癌(mCRC)患者抗表皮生长因子受体单克隆抗体靶向耐药的预测性生物标志物。HER2双重抑制剂曲妥珠单抗联合拉帕替尼或帕妥珠单抗初步显示出对RAS野生型mCRC患者良好的抗肿瘤效果。HER2靶向治疗策略有可能改变mCRC患者临床相关亚群的治疗模式。
Several studies have shown that human epidermal growth factor receptor 2(HER2)amplification could be a predictive biomarker of resistance to anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS wild-type metastatic colorectal cancer(mCRC).Dual HER2 inhibition with trastuzumab plus lapatinib or pertuzumab has shown promising preliminary anti-tumoral efficacy in RAS wild-type mCRC.HER2-targeted therapeutic strategies have the potential to change the treatment paradigm for a clinically relevant subgroup of patients with mCRC.
作者
于姣姣
王军
王利康
姚南
Yu Jiaojiao;Wang Jun;Wang Likang;Yao Nan(First School of Clinical Medicine of Lanzhou University,Lanzhou 730000,China;Department of General Surgery,First Hospital of Lanzhou University,Lanzhou 730000,China)
出处
《国际肿瘤学杂志》
CAS
2021年第4期246-249,共4页
Journal of International Oncology
